Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM19GUH)

• Drug Name: TVB-2640 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Astrocytoma	2A00.0Y	Phase 2	[1]
Colon cancer	2B90.Z	Phase 2	[1]
Non-alcoholic fatty liver disease	DB92	Phase 2	[2]
Advanced solid tumour	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 66548316
  TTD Drug ID: DM19GUH

Molecule-Related Drug Atlas

Drug(s) Targeting Fatty acid synthase (FASN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[5]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[6]
FAS1	DMAX2EW	Fungal infection	1F29-1F2F	Preclinical	[7]
FSA2	DMLNRCI	Fungal infection	1F29-1F2F	Preclinical	[7]
MORIN	DM2OGZ5	Discovery agent	N.A.	Investigative	[6]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[6]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[6]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[6]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[8]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[6]
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[5]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[6]
FAS1	DMAX2EW	Fungal infection	1F29-1F2F	Preclinical	[7]
FSA2	DMLNRCI	Fungal infection	1F29-1F2F	Preclinical	[7]
MORIN	DM2OGZ5	Discovery agent	N.A.	Investigative	[6]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[6]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[6]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[6]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[8]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT03938246) Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02223247) A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [4] Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
• [5] Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
• [6] Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
• [7] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [8] 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.